Payment overview · 2025
General Payments
$554.65
30 reported records · 18 companies
Healthcare provider profile · identity verified
Melmoth Suhr Patterson, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAURENS, SC · NPI 1558464792
Verified facts
What the public records show
CMS Open Payments records show Melmoth Suhr Patterson, MD received $554.65 in general payments during 2025 across 30 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $89.44 | 16.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.76 | 9.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.45 | 8.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $44.11 | 8.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.61 | 7.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.73 | 5.7% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $29.38 | 5.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.66 | 5.2% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $27.24 | 4.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.48 | 4.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.23 | 4.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.45 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.88 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.61 | 3.2% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $14.96 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.67 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.30 | 2.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.69 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $554.65 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $133.55 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.61 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 319 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 99 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
143 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
99 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
137 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 37 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
99 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1589 | 192 |
| Atorvastatin Calcium | Atorvastatin Calcium | 943 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 845 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 832 | 136 |
| Alprazolam | Alprazolam | 802 | 81 |
| Gabapentin | Gabapentin | 762 | 142 |
| Furosemide | Furosemide | 756 | 147 |
| Potassium Chloride | Potassium Chloride | 635 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 622 | 122 |
| Omeprazole | Omeprazole | 619 | 114 |
| Lorazepam | Lorazepam | 612 | 100 |
| Citalopram Hbr | Citalopram Hydrobromide | 546 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 530 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 530 | 125 |
| Losartan Potassium | Losartan Potassium | 504 | 118 |
| Famotidine | Famotidine | 463 | 103 |
| Lisinopril | Lisinopril | 431 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 412 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 400 | 88 |
| Metformin Hcl | Metformin Hcl | 395 | 71 |
| Trazodone Hcl | Trazodone Hcl | 395 | 71 |
| Tramadol Hcl | Tramadol Hcl | 382 | 80 |
| Eliquis | Apixaban | 374 | 53 |
| Jardiance | Empagliflozin | 319 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 313 | 64 |
| Meloxicam | Meloxicam | 313 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 304 | 64 |
| Clonazepam | Clonazepam | 300 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 295 | 55 |
| Temazepam | Temazepam | 295 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 282 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 270 | 57 |
| Glimepiride | Glimepiride | 256 | 52 |
| Simvastatin | Simvastatin | 256 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 51 |
| Spironolactone | Spironolactone | 244 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 237 | 85 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 230 | 49 |
| Carvedilol | Carvedilol | 229 | 50 |
| Mirtazapine | Mirtazapine | 225 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 215 | 43 |
| Donepezil Hcl | Donepezil Hcl | 205 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 203 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 200 | 32 |
| Montelukast Sodium | Montelukast Sodium | 187 | 43 |
| Ozempic | Semaglutide | 185 | 37 |
| Pregabalin | Pregabalin | 175 | 32 |
| Diazepam | Diazepam | 173 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 173 | 30 |
| Sertraline Hcl | Sertraline Hcl | 172 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 26 |
| Myrbetriq | Mirabegron | 163 | 14 |
| Prednisone | Prednisone | 161 | 56 |
| Amitriptyline Hcl | Amitriptyline Hcl | 160 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 160 | 45 |
| Allopurinol | Allopurinol | 158 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 157 | 72 |
| Fluoxetine Hcl | Fluoxetine Hcl | 155 | 32 |
| Atenolol | Atenolol | 149 | 24 |
| Metformin Hcl Er | Metformin Hcl | 144 | 35 |
| Farxiga | Dapagliflozin Propanediol | 143 | 16 |
| Cephalexin | Cephalexin | 138 | 97 |
| Entresto | Sacubitril/Valsartan | 137 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 24 |
| Memantine Hcl | Memantine Hcl | 131 | 20 |
| Azithromycin | Azithromycin | 130 | 91 |
| Finasteride | Finasteride | 125 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 20 |
| Topiramate | Topiramate | 117 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 116 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 37 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 114 | 14 |
| Xarelto | Rivaroxaban | 113 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 112 | 16 |
| Nystatin | Nystatin | 102 | 52 |
| Rexulti | Brexpiprazole | 99 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 78 |
| Fluconazole | Fluconazole | 97 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 96 | 61 |
| Bupropion Xl | Bupropion Hcl | 94 | 24 |
| Promethazine Hcl | Promethazine Hcl | 94 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 93 | 18 |
| Estradiol | Estradiol | 93 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 89 | 12 |
| Torsemide | Torsemide | 82 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 18 |
| Amoxicillin | Amoxicillin | 79 | 60 |
| Nitroglycerin | Nitroglycerin | 78 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 20 |
| Lovastatin | Lovastatin | 76 | 11 |
| Celecoxib | Celecoxib | 73 | 14 |
| Naproxen | Naproxen | 72 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 17 |
| Meclizine Hcl | Meclizine Hcl | 71 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 14 |
| Ezetimibe | Ezetimibe | 69 | 16 |
| Risperidone | Risperidone | 68 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 67 | 27 |
| Clonidine Hcl | Clonidine Hcl | 65 | 12 |
| Glipizide Er | Glipizide | 65 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 65 | suppressed |
| Aripiprazole | Aripiprazole | 64 | 11 |
| Sucralfate | Sucralfate | 64 | 19 |
| Ondansetron Odt | Ondansetron | 61 | 28 |
| Ibuprofen | Ibuprofen | 60 | 17 |
| Acebutolol Hcl | Acebutolol Hcl | 56 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 56 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 13 |
| Baclofen | Baclofen | 52 | suppressed |
| Latanoprost | Latanoprost | 50 | 11 |
| Glipizide | Glipizide | 47 | 12 |
| Bumetanide | Bumetanide | 46 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | suppressed |
| Colchicine | Colchicine | 42 | 12 |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 42 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Calcitriol | Calcitriol | 40 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Linzess | Linaclotide | 38 | 11 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Premarin | Estrogens, Conjugated | 33 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Fentanyl | Fentanyl | 31 | suppressed |
| Calcium Acetate | Calcium Acetate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Mupirocin | Mupirocin | 26 | 17 |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Nadolol | Nadolol | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 17 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 16 |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Epinephrine | Epinephrine | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $554.65 · 30 records | Otsuka America Pharmaceutical, Inc. | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CT THROMBECTOMY SYSTEM KIT, FANAPT, FLOWTRIEVER CATHETER, S, HETLIOZ, INJECTAFER, INSPIRE, JARDIANCE, KISUNLA, Korlym, LAGEVRIO, LEQVIO, MOUNJARO, NEXLETOL, Ozempic, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, The Cologuard Plus Collection Kit, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error